logo
Southeast Asia pharma market set to outgrow global average

Southeast Asia pharma market set to outgrow global average

Focus Malaysia5 days ago
SOUTHASIA Asia (SEA) presents a substantial future prospect for the pharmaceutical market. Its projected growth rate significantly outpaces the global average and other major established markets.
As of calendar year 2024 (CY24), global total market size for pharmaceuticals is estimated at USD1.5 tri. In comparison, SEA's total market size is estimated at USD27 bil.
The significant growth for SEA indicates that ASEAN is a prime growth engine for the global pharmaceutical industry. This makes it an attractive destination for investment and market expansion.
The Philippines and Malaysia show steady growth in a biosimilar export potential, reaching USD 111 mil and USD 70 mil respectively by 2027.
Malaysia's growth, though robust, is relatively smaller in absolute terms compared to Thailand, Vietnam, and Indonesia.
However, companies like Duopharma and Pharmaniaga are actively developing Halal-certified biosimilars.
Overall, biosimilars is an untapped potential due to increasing healthcare demands and cost pressure.
'We believe that investing in local manufacturing of biosimilars can open avenues for SEA countries to export,' said MBSB Research.
Countries that prioritise and invest in local biosimilar production are likely to become stronger exporters in this field.
This aligns with the broader trends of high pharmaceutical market growth in SEA driven by demographics, NCDs, and the increasing sophistication of healthcare systems, all of which necessitate tailored and creative market strategies.
Malaysia's pharmaceutical sector boasts a strong and strategically recognized local manufacturing base that significantly contributes to medicine security, especially for generics and essential medicines.
While Malaysia demonstrates capabilities in exporting to highly regulated markets like the USA, it remains heavily reliant on imports for patented drugs, biologics, vaccines, and key APIs.
The main challenge for Malaysia lies in bridging this gap by further boosting local R&D, attracting more sophisticated manufacturing capabilities, and strengthening its position in the global pharmaceutical value chain beyond just generics.
79% of total volume of generic medicines and 47% of items listed in National Essential Medicines List (NEML) are locally produced.
However, most drugs, notably patented medicaments, immunoglobulins, human vaccines and insulins, are still dependent on imports.
Malaysia consistently shows widening trade deficit underscores Malaysia's high reliance on imported pharmaceuticals.
While local production is strong in generics, the country still depends heavily on foreign sources for innovative, patented, and specialised medicines.
This reinforces the government's strategic focus on local manufacturing and technology transfer to enhance medicine security and reduce import dependency in the long run.
The overall trend in the regional and local pharmaceutical market suggests that both domestic and foreign investors will see growing opportunities in Malaysia.
The 51% FDI / 49% DDI ratio suggests a healthy balance between local commitment, and global capital and expertise.
FDI indicates that Malaysia is highly attractive to foreign pharmaceutical companies, bringing in capital, technology, and global best practices, while DDI signifies robust local entrepreneurship and investment from Malaysian companies, demonstrating confidence in the domestic market and capabilities.
We opine that the untapped drug manufacturing ecosystem will continue to follow the megatrend of new innovative drugs – including biologics, biosimilars and cell & gene therapy drugs – and open more opportunities for Malaysia to be a major healthcare hub in the region.
While direct pharmaceutical exports from Malaysia to the US might face immediate headwinds from tariffs, the broader impact on Malaysia's healthcare subsector could come from indirect effects on global pharmaceutical supply chains and procurement costs.
This would affect the affordability and availability of medicines within Malaysia for all citizens and healthcare providers.
The Malaysian government and industry players are already responding by prioritizing supply chain diversification and exploring domestic production enhancements to mitigate these risks.
Meanwhile, we believe a multi-pronged approach involving government action, industry adaptation, and consumer awareness will be crucial.
Overall, we maintain positive on the healthcare sector. The pharmaceutical market is fundamentally driven by robust demographic trends, which naturally increases the demand for healthcare services and medicines. —July 23, 2025
Main image: Daily Sabah
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DIFC's H1 2025 results fuel Dubai's economic vision (D33) and demonstrate global leadership in financial services and innovation
DIFC's H1 2025 results fuel Dubai's economic vision (D33) and demonstrate global leadership in financial services and innovation

Malaysian Reserve

time4 hours ago

  • Malaysian Reserve

DIFC's H1 2025 results fuel Dubai's economic vision (D33) and demonstrate global leadership in financial services and innovation

DUBAI, UAE, July 28, 2025 /PRNewswire/ — Dubai International Financial Centre (DIFC), the leading global financial centre in the Middle East, Africa and South Asia (MEASA), announced its best-ever performance for the first half of a year, reinforcing its contribution in driving the future of finance and the Dubai Economic Agenda (D33). DIFC saw a record 1,081 new active registered companies join the Centre during the first six months of 2025 bringing the total number of active registered companies to 7,700. 47,901 professionals now work in DIFC. Total Financial services authorisations grew 28 per cent year-on-year – 78 in H1 2025 compared to 61 in H1 2024. DIFC's banking and capital markets cluster consists of 289 companies, up from 247 a year ago. The number of firms in the wealth and asset management sector increased to 440, up from 370 in H1 2024, growing 19 per cent year-on-year, with 85 hedge funds, including 69 billion-dollar funds. Over 10,000 funds are being managed or marketed from DIFC. Additionally, 1,035 entities associated with family businesses now operate from the Centre, up from 600 a year ago. The number of foundations in DIFC have accelerated to 842, up from 548 in H1 2024. 135 insurance-related firms operate from DIFC. Gross Written Premiums advanced to USD 3.5bn for 2024, compared to USD 2.6bn a year earlier. The number of FinTech and Innovation companies reached 1,388, up from 1,081 in H1 2024 a surge of 28 per cent. Total active non-financial entities increased to 6,335, up from 4,935 a year earlier. H.E. Essa Kazim, Governor of DIFC said: 'DIFC remains the driving force behind Dubai's economic growth, as a key enabler of the financial services sector's expansion and diversification. Our consistent performance across all sectors and rising global standing strengthen our commitment to supporting innovation, attracting global capital, and reinforcing Dubai's status as one of the world's most competitive and diversified economies.' Dubai is one of eight cities globally to possess 'broad and deep' capabilities across all parts of the finance industry in the Global Financial Centres Index, alongside London, New York, and Paris. Over 1.6mn sq. ft. of commercial space is currently under development and construction being accelerated to meet demand. The new space will be ready for occupancy starting from Q1 2026. Photo – – View original content:

Foreign, institutional investors net sold on Bursa Malaysia last week
Foreign, institutional investors net sold on Bursa Malaysia last week

Malaysian Reserve

time10 hours ago

  • Malaysian Reserve

Foreign, institutional investors net sold on Bursa Malaysia last week

FOREIGN investors extended their net selling streak on Bursa Malaysia to three consecutive weeks while local institutions extended their net selling streak to two consecutive weeks. Foreign investors registered a net outflow of RM89.9 million for the week ended July 25, smaller than previous week outflow of RM206.1 million, according to a fund flow report by MBSB Research, formerly known as MIDF Research. The top counters net sold by foreign investors were Zetrix AI Bhd, KPJ Healthcare Bhd and Public Bank, RHB Bank Bhd and Alliance Bank Malaysia Bhd. The report said local retailers continued their net buying activities, extending to a three-week consecutive streak of purchases, posting a net inflow of RM105.4 million. — TMR

Selling by foreign funds on Bursa stretches to a third successive week with RM90m net outflow
Selling by foreign funds on Bursa stretches to a third successive week with RM90m net outflow

Focus Malaysia

time12 hours ago

  • Focus Malaysia

Selling by foreign funds on Bursa stretches to a third successive week with RM90m net outflow

FOREIGN investors extended their net selling streak to a third straight week to register a net outflow of -RM89.9 mil during the July 21-25 trading period although this was smaller than the previous week's outflow of -RM206.1 mil. They were net sellers on every trading session except Wednesday (July 23) and Thursday (July 24) with outflows ranging from -RM21.0 mil to -RM136.5 mil, according to MBSB Research (previously MIDF Research). 'The largest outflow was recorded on Friday (July 25), followed by Monday (July 21) with -RM52.3 mil and Tuesday (July 22) with -RM21.0 mil,' observed the research house. 'Wednesday (July 23) and Thursday (July 24) recorded net inflows of RM97.3 mil and RM22.6 mil respectively.' The top three sectors that recorded the highest net foreign inflows were transportation & logistics (RM158.7 mil), utilities (RM69.5 mil) and construction (RM51.4 mil). On the contrary, the top three sectors that recorded the highest net foreign outflows were financial services (-RM174.1 mil), technology (-RM80.8 mil) and telco & media (-RM70.8 mil). Tracking the foreign investors, local institutions, too, extended their net selling streak to two consecutive weeks by posting a net outflow of -RM15.5 mil which was smaller than the previous week's outflow of -RM33.3 mil. However, local retailers continued their net buying activities by extending their purchase streak to a third week in a row with a net inflow of RM105.4 mil. The average daily trading volume (ADTV) experienced a broad-based decline last week. Foreign investors and local retailers recorded decreases of -5.5% and -2.1% respectively while local institutions saw a modest decline of -0.8%. In comparison with another four Southeast Asian markets tracked by MIDF Research, Thailand attracted a net inflow of US$273.3 mil to extend its streak of foreign purchases to a third consecutive week. This was followed by the Philippines which posted a modest net inflow of US$6.0 mil to break two consecutive weeks of outflows. However, Indonesia posted a net outflow of -USD8.2 mil – its sixth successive week of foreign selling – while Vietnam's net flow data was again unavailable at the time of writing. The top three stocks with the highest net money inflow from foreign investors last week were Westports Holdings Bhd (RM162.0 mil), Tenaga Nasional Bhd (RM94.7 mil) and Gamuda Bhd (RM75.3 mil). – July 28, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store